MedTrace Logo

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

NCT05688280 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-01-08

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.

Conditions

  • Metastatic Solid Tumor
  • Colon Cancer
  • Nonsmall Cell Lung Cancer
  • Soft Tissue Sarcoma

Interventions

DRUG

1.0% IP-001 for Injection

4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Sponsors & Collaborators

  • Immunophotonics, Inc.

    lead INDUSTRY

Principal Investigators

  • Markus Jorger, MD · Cantonal Hospital of St. Gallen

  • Diane Beatty, PhD · Immunophotonics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2025-02-28
Completion
2025-02-28
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05688280 on ClinicalTrials.gov